Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

PURPOSE. A phase III, randomized, double-blind, placebo-controlled trial was conducted in patients with metastatic renal cell carcinoma. The focus of this paper is to evaluate the patient-reported outcomes. METHODS. Patients were randomly assigned (2:1) to receive oral everolimus 10 mg once daily or...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Beaumont, Jennifer L., Butt, Zeeshan, Baladi, Jeanfrancois, Motzer, Robert J., Haas, Tomas, Hollaender, Norbert, Kay, Andrea, Cella, David
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2011
Assuntos:
Genitourinary Cancer: Renal, Bladder, and Testicular
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228193/
https://ncbi.nlm.nih.gov/pubmed/21459902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0299
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares